Research at Oslo University Hospital

 

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

 

Latest news

Oslo University Hospital research seminar Monday May 9th

Discovery of biologically active small molecular compounds

 

Welcome to the next Oslo University Hospital (OUH) research seminar entitled
"Discovery of biologically active small molecular compounds"

Time: Monday, May 9th, 2016, at 14:30 – 16:10.
Place: Red Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo.

Speakers: Kjetil Taskén, Phil Gribbon, Anne Jorunn Stokke, Jarl Underhaug, Jeanette H. Andersen, Geir Klinkenberg and Lina Prasmickaite

 
 

OUS scientists co-author Nature article:

Mapping somatic mutations in breast cancer whole genomes

 
From left: Miriam R. Aure, Ole Chr. Lingjærde, Anita Langerød and Anne-Lise Børresen-Dale
From left: Miriam R. Aure, Ole Chr. Lingjærde, Anita Langerød and Anne-Lise Børresen-Dale

The most comprehensive analysis to date of somatic (acquired) mutations, across whole-genome sequences for breast cancer, is reported in a paper published in the May 2nd edition of Nature (journal impact factor 41.5).
Miriam R. Aure, Anita Langerød, Ole Christian Lingjærde, and Anne-Lise Børresen-Dale from the "Molecular biology of breast cancer group" at the Department of Cancer Genetics has contributed substantially to the study.
A related paper, published in Nature Communications, explores how these mutations relate to aspects of genome structure. Together, the studies highlight the repertoire of genes and mutational processes involved in breast cancer and move us closer to a more complete account of the genetic basis of the disease.

 
 

Institute for Cancer Research annual report 2015

 

2015 has been a very good year for ICR, and areas for further improvement include increases in collaboration with clinical researchers, partnerships and coordinator roles in more successful EU grants, and strengthened international visibility. 

Read all the details in the recently published annual report.

 
 

Same, but different? Genetic analysis of five immune mediated diseases reveals molecular taxonomy of chronic inflammation

 
Tom Hemming Karlsen
Tom Hemming Karlsen

A genetic analysis recently published in Nature Genetics (journal impact factor 29.35) sheds new light on the high comorbidity between primary sclerosing cholangitis (PSC) and inflammatory bowel disease.
Researchers from four large disease consortia, encompassing hundreds of researchers from 26 countries, joined forces to combine data from studies of their respective diseases, amounting to 52,262 patients and 34,213 healthy controls.
“This study is important because it creates a platform for understanding the molecular make-up of each disease, in the future enabling more specified treatment of chronic inflammatory disease”, says Tom Hemming Karlsen, coordinator of one of the participating consortia.

 
 

Article published in Science Translational Medicine showing that cyclodextrin may reduce atherosclerosis attracts worldwide attention

 
Halvorsen (left) and Skjelland
Halvorsen (left) and Skjelland

Two OUS researchers - professor Bente Halvorsen from the Research Institute of Internal Medicine, and head physician Mona Skjelland from the Department of Neurology - have together with professor Terje Espevik and post doc Siril Bakke from NTNU participated in a large international research project where they have shown that cyclodextrin may reverse atherosclerosis. The study is run by a German research group led by professor Eicke Latz, and the results were recently published in Science Translational Medicine (journal impact factor 18.54). The research has also received widespread attention from various places, including two highly profiled articles in the major newspaper Wall Street Journal.
(story updated with more links to articles from various news sources, under "More")

 
 

The Fridtjof Nansen Award for Young Scientists for 2016 to Kyrre Eeg Emblem

 
Kyrre E. Emblem
Kyrre E. Emblem

The Fridtjof Nansen Award of Excellence is awarded to Norwegian researchers, or researchers resident in Norway, who has shown scientific contributions of international significance on a very high level.

Fridtjof Nansen Award for Young Scientists for 2016 is divided between Professor Magne Mogstad at the Department of Economics, University of Chicago, for his outstanding research in the fields of economics and Principal Investigator Kyrre Eeg Emblem from the Intervention Centre at Oslo University Hospital, for his outstanding contribution to medical diagnostics.

The awards are presented by the chairman of The Nansen Foundation and Affiliated Funds, Professor Øyvind Østerud, on the Annual meeting of The Norwegian Academy of Science and Letters on Tuesday 3 May, 2016 at the Grand Hotel, Oslo.

 
 

Theodossiou and Berg funded by the Future and Emerging Technology (FET) program

 
Kristian Berg (left) and Theodossis Theodossiou
Kristian Berg (left) and Theodossis Theodossiou

Theodossis Theodossiou and Kristian Berg from the Photochemical internalisation (PCI) group at the Department of Radiation Biology have been funded by the Future and Emerging Technology (FET) program under the Excellent Science section of the Horizon 2020 EU Framework for Research and Innovation. The FET program funded this time 11 projects out of 820 grant applications (1,4 % success rate) and the proposal by Theodossiou and Berg was rated as no. 6. The project receives 3 million Euros together with 3 collaborating academic partners as well as one commercial partner (SME) from UK. The project, named Lumiblast, will be coordinated by Kristian Berg. This is the first time Norway is the coordinator of a FET project.

 
 

King Olav V's cancer research prize for 2016 to Kjetil Taskén

 
Kjetil Taskén (photo: nyebilder.no)
Kjetil Taskén (photo: nyebilder.no)

King Olav V's cancer research prize for 2016 goes to Kjetil Taskén. He receives the award for his outstanding work in the field of immunotherapy.
The award will be handed over by HM King Harald V on behalf of the Norwegian Cancer Society in Oslo June 6th. The prestigious prize is distributed annually by the Norwegian Cancer Society, and the winner receives NOK 1.000.000.
Taskén has been Director of the Centre for Molecular Medicine Norway (NCMM) since 2009 and Director of the Biotechnology Centre of Oslo since 2003. He also has a position as a senior researcher at the Department of Infectious Diseases at the Division of Medicine, Oslo University Hospital.

 
 

Oslo University Hospital research seminar Monday March 14th

Microbiome

 

Welcome to the next Oslo University Hospital (OUH) research seminar entitled "Microbiome".

Time: Monday, March 14th, 2016, at 14:30 – 16:00.
Place: Blue Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo.

Speakers: Tone Tønjum, Merete Eggesbø, Martin Kummen and Marius Trøseid.

 
 

The Norwegian Inflammation Network seminar Wednesday March 16th

Morgendagens medisin

 

The Norwegian Inflammation Network (NORIN) is holding a seminar on Wednesday, 16 March entitled "Morgendagens medisin."
Time and Place: 3 PM (15.00), Domus Medica, “Rotunde,” Runde auditorium (GA21 R-105), Sognvannsveien 9, University of Oslo
Refreshments will be served after the program.